This site is intended for US Health Care Professionals only.
LUZU STRENGTH
Due to Trichophyton rubrum and Epidermophyton floccosum in adults
STRIKE NOW. TREAT FAST.
2 weeks, 14 doses for tinea pedis; efficacy seen at 4 weeks post-treatment
1 week, 7 doses for tinea cruris and tinea corporis; efficacy seen at 3 weeks post-treatment
LUZU is an FDA-approved prescription topical cream proven to treat interdigital tinea pedis, tinea cruris, and tinea corporis.
$0co-payfor eligible patients*LUZU may help some patients with interdigital tinea pedis become fungus free. Individual results may vary.
Indications and Usage
LUZU (luliconazole) Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum in patients 18 years of age and older.
Important Safety Information
LUZU is indicated for topical use only and is not indicated for ophthalmic, oral or intravaginal use.
LUZU should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Caution should be exercised when LUZU is prescribed for nursing mothers.
The most common adverse reactions in clinical trials were application site reactions, which occurred in less than 1% of subjects in both LUZU and vehicle arms. Most adverse reactions were mild in severity.
Click here for LUZU Prescribing Information.
*Offer valid for commercially insured patients whose insurance covers LUZU. Commercially insured patients whose insurance does not cover LUZU may pay more. Cash-paying patients are not eligible. This or any other offer is not valid for prescriptions reimbursed in whole or in part by Medicaid, Medicare, or any other federal or state programs (including VA, DOD, Tricare, and any state prescription drug programs). Please see coupon for full terms and conditions.
®/TMs are trademarks of Valeant Pharmaceuticals International, Inc. or its affiliates. Any other product or brand names and logos are the property of their respective owners.
©2015 Valeant Pharmaceuticals North America LLC. DM/LUZ/15/0135